Neogen Chemicals 경영진
경영진 기준 점검 4/4
Neogen Chemicals CEO는 Harin Kanani, Oct2025 에 임명되었습니다 의 임기는 1년 미만입니다. 총 연간 보상은 ₹15.00M, 90.7% 급여 및 9.3% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 ₹9.11B 가치에 해당하는 회사 주식의 17.02% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 2.3 년과 8.5 년입니다.
핵심 정보
Harin Kanani
최고경영자
₹15.0m
총 보수
| CEO 급여 비율 | 90.67% |
| CEO 재임 기간 | less than a year |
| CEO 지분 보유율 | 17.0% |
| 경영진 평균 재임 기간 | 2.3yrs |
| 이사회 평균 재임 기간 | 8.5yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • Jun 16
NEOGEN: Preferential Share Issue Will Keep Future P E Excessively Elevated
Analysts have kept their fair value estimate for Neogen Chemicals steady at ₹1,455, citing relatively unchanged assumptions around revenue growth, profit margins and future P/E multiples, along with a slightly lower discount rate that fine tunes but does not materially shift their overall price target view. What’s in the News for Neogen Chemicals A board meeting is scheduled on May 16, 2026 to consider audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to consider a final dividend recommendation for approval at the 37th AGM.내러티브 업데이트 • Jun 02
NEOGEN: Preferential Equity Issue Will Sustain Pressure On Elevated Future P E
Analysts have raised their price target on Neogen Chemicals from ₹1,335 to ₹1,455, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. What's in the News Board meeting scheduled for May 16, 2026 to consider audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to consider recommending a final dividend on equity shares, subject to shareholder approval at the 37th AGM.분석 기사 • May 24
Neogen Chemicals' (NSE:NEOGEN) Problems Go Beyond Weak Profit
The market wasn't impressed with the soft earnings from Neogen Chemicals Limited ( NSE:NEOGEN ) recently. We did some...
내러티브 업데이트 • May 11
NEOGEN: Preferential Equity Funding Will Support Long Term Upside Potential
Analysts have trimmed their price target for Neogen Chemicals from ₹2,630 to about ₹2,311 as they factor in more moderate revenue growth assumptions, a slightly higher profit margin outlook, and a lower future P/E multiple in their models. What's in the News Board meeting scheduled for April 18, 2026, to consider allotment of 1,000,000 equity shares with face value of ₹10 at an issue price of ₹1,610 per share on a preferential basis, aggregating up to ₹1,610,000,000.내러티브 업데이트 • Apr 23
NEOGEN: Equity Fundraising Plans Will Pressure Elevated Future P E Multiple
Analysts have kept their price target for Neogen Chemicals steady at ₹1,335, citing only small refinements to their discount rate, revenue growth outlook and profit margin assumptions, along with a slightly lower future P/E multiple, rather than any major shift in the investment case. What's in the News On February 11, 2026, the board met to review unaudited standalone and consolidated results for the quarter and nine months ended December 31, 2025, and to evaluate various options for raising funds through equity and other securities in one or more tranches (company filing).내러티브 업데이트 • Apr 09
NEOGEN: Future PE Reset Will Test Sustainability Of Recent Cost Improvements
Narrative Update Analysts have held the fair value estimate for Neogen Chemicals steady at ₹1,335.00 while updating assumptions on growth, margins and future P/E. This reflects recent research that cites stronger revenue and EBITDA performance, cost actions taking hold and higher external price targets in the range of roughly ₹540 to ₹1,000 equivalent.
내러티브 업데이트 • Mar 25
NEOGEN: Raised Guidance And Cost Actions Will Support Higher Future Earnings Quality
Narrative Update Overview The revised analyst price target for Neogen Chemicals edges slightly lower to ₹1,756.25 from ₹1,769.57. This reflects updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, while staying broadly aligned with recent Street research that has cited better revenue and EBITDA prints, higher guidance, and early benefits from cost actions.내러티브 업데이트 • Mar 10
NEOGEN: Future P E Compression Will Challenge Optimism Around Cost Driven Margin Gains
Our updated fair value estimate for Neogen Chemicals shifts to ₹1,335 from ₹1,670 as analysts factor in slightly adjusted growth assumptions, a modestly lower discount rate, firmer profit margins and a reduced future P/E multiple, broadly in line with recent Street research that links higher targets in other names to improving revenue quality, cost actions and guidance. Analyst Commentary Street research around Neogen Chemicals points to a more measured setup, even as some peers in the sector see higher optimism baked into targets.내러티브 업데이트 • Feb 24
NEOGEN: Raised Guidance And Cost Actions Will Support Richer Future Earnings Multiple
Analysts have trimmed their fair value estimate for Neogen Chemicals from ₹1,847 to about ₹1,770, as slightly softer revenue growth and margin inputs are being offset by a higher assumed future P/E multiple and recent Street target hikes following better than expected earnings and guidance. Analyst Commentary Recent Street research around Neogen Chemicals reflects a mix of optimism about execution and some caution on how durable the current momentum might be for earnings and valuation.내러티브 업데이트 • Feb 10
NEOGEN: Raised Guidance And Cost Actions Will Support Further Upside
Narrative Update: Neogen Chemicals Analysts have lifted their price target on Neogen Chemicals to a range of about $10 to $12, up from $6.50 to $8. This change is attributed to the company’s recent revenue and EBITDA beat, raised guidance, and early benefits from portfolio execution and cost actions.내러티브 업데이트 • Jan 26
NEOGEN: Raised Guidance And Upcoming Board Results Will Support Upside
Narrative Update The analyst price target for Neogen Chemicals has been adjusted from approximately ₹1,812 to ₹1,847 as analysts factor in recent research that points to steady fair value assumptions, a slightly higher discount rate, unchanged growth and margin inputs, and a modestly higher future P/E multiple in light of recent earnings commentary and guidance updates on Neogen. Analyst Commentary Recent Street research on Neogen Chemicals highlights a mix of optimism around execution and guidance, paired with some restraint on how far the valuation should stretch after the latest earnings release.내러티브 업데이트 • Jan 09
NEOGEN: Steady Fair Value And Upcoming Results Will Support Upside
Analysts have kept their fair value estimate for Neogen Chemicals steady at ₹1,812.29 per share, with only marginal adjustments to the discount rate, revenue growth, profit margin and future P/E inputs that are too small to materially change the target at this time. What's in the News Board meeting scheduled for November 8, 2025, at 14:30 Indian Standard Time to review and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).내러티브 업데이트 • Dec 26
NEOGEN: Market Perform Initiation Will Support Upside From Resilient Margins
Analysts have modestly revised their price target on Neogen Chemicals upward to $10, reflecting slightly higher long term growth expectations and largely stable margin and valuation assumptions. Analyst Commentary The latest initiation at a Market Perform rating with a $10 price target highlights a balanced view on Neogen Chemicals, with analysts seeing the current valuation as broadly aligned with its near to medium term growth prospects.내러티브 업데이트 • Dec 11
NEOGEN: Market Perform Initiation Will Support Steady Future Return Potential
Analysts have nudged their price target for Neogen Chemicals slightly higher, reflecting a modest improvement in fair value to roughly ₹1,812 per share. This is supported by expectations of sustained high revenue growth and stable valuation multiples, despite only minor adjustments to discount rate and profit margin assumptions.분석 기사 • Dec 04
Why We're Not Concerned Yet About Neogen Chemicals Limited's (NSE:NEOGEN) 26% Share Price Plunge
The Neogen Chemicals Limited ( NSE:NEOGEN ) share price has fared very poorly over the last month, falling by a...내러티브 업데이트 • Nov 27
NEOGEN: Broader Customer Base And Joint Venture Will Support Steady Future Returns
Analysts have maintained Neogen Chemicals' price target at $1,806.57, citing stable growth expectations and aligning their assessment with the recent initiation of a Market Perform rating by the Street. Analyst Commentary Bullish Takeaways Bullish analysts note Neogen Chemicals' consistent revenue growth, which supports the current valuation and underpins the stable price target.분석 기사 • Nov 16
We Think That There Are More Issues For Neogen Chemicals (NSE:NEOGEN) Than Just Sluggish Earnings
Neogen Chemicals Limited's ( NSE:NEOGEN ) earnings announcement last week contained some soft numbers, disappointing...분석 기사 • Nov 14
Analysts Are More Bearish On Neogen Chemicals Limited (NSE:NEOGEN) Than They Used To Be
One thing we could say about the analysts on Neogen Chemicals Limited ( NSE:NEOGEN ) - they aren't optimistic, having...내러티브 업데이트 • Nov 12
NEOGEN: Product Diversification Will Drive Long-Term Returns After New Joint Venture
Analysts have revised Neogen Chemicals' fair value target downward from ₹2,062.83 to ₹1,806.57. This adjustment is due to a slightly higher discount rate and moderated revenue growth expectations, as reflected in recent research updates.분석 기사 • Nov 11
These 4 Measures Indicate That Neogen Chemicals (NSE:NEOGEN) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...내러티브 업데이트 • Aug 06
Expanding Lithium Battery Materials Will Secure Global Reach
Despite an upward revision in revenue growth forecasts, Neogen Chemicals’ consensus price target has been lowered to ₹2,062, primarily due to a substantial decline in its future P/E multiple. What's in the News Annual dividend decreased to INR 1 per share for FY 2024-25.
새로운 내러티브 • Mar 15
Merger With BuLi Chemicals Will Strengthen Market Position In Pharma And Agrochemicals
The merger and strategic product expansions aim to strengthen Neogen's market position and boost future export and domestic revenue growth.분석 기사 • Feb 21
Neogen Chemicals Limited's (NSE:NEOGEN) P/S Is On The Mark
When you see that almost half of the companies in the Chemicals industry in India have price-to-sales ratios (or "P/S...분석 기사 • Feb 06
Neogen Chemicals Limited Just Missed Earnings - But Analysts Have Updated Their Models
It's been a pretty great week for Neogen Chemicals Limited ( NSE:NEOGEN ) shareholders, with its shares surging 16% to...분석 기사 • Dec 26
Here's Why Neogen Chemicals (NSE:NEOGEN) Has A Meaningful Debt Burden
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Dec 10
The Returns On Capital At Neogen Chemicals (NSE:NEOGEN) Don't Inspire Confidence
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...분석 기사 • Nov 20
Why Neogen Chemicals' (NSE:NEOGEN) Shaky Earnings Are Just The Beginning Of Its Problems
A lackluster earnings announcement from Neogen Chemicals Limited ( NSE:NEOGEN ) last week didn't sink the stock price...분석 기사 • Nov 16
Earnings Miss: Neogen Chemicals Limited Missed EPS By 6.7% And Analysts Are Revising Their Forecasts
Last week, you might have seen that Neogen Chemicals Limited ( NSE:NEOGEN ) released its second-quarter result to the...분석 기사 • Sep 20
Investors Appear Satisfied With Neogen Chemicals Limited's (NSE:NEOGEN) Prospects As Shares Rocket 36%
The Neogen Chemicals Limited ( NSE:NEOGEN ) share price has done very well over the last month, posting an excellent...분석 기사 • May 08
We Think That There Are More Issues For Neogen Chemicals (NSE:NEOGEN) Than Just Sluggish Earnings
Neogen Chemicals Limited's ( NSE:NEOGEN ) recent weak earnings report didn't cause a big stock movement. We think that...분석 기사 • May 05
Earnings Miss: Neogen Chemicals Limited Missed EPS By 24% And Analysts Are Revising Their Forecasts
As you might know, Neogen Chemicals Limited ( NSE:NEOGEN ) last week released its latest full-year, and things did not...분석 기사 • Apr 26
After Leaping 27% Neogen Chemicals Limited (NSE:NEOGEN) Shares Are Not Flying Under The Radar
Neogen Chemicals Limited ( NSE:NEOGEN ) shares have had a really impressive month, gaining 27% after a shaky period...분석 기사 • Apr 12
Are Neogen Chemicals Limited (NSE:NEOGEN) Investors Paying Above The Intrinsic Value?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Neogen Chemicals fair value estimate is ₹1,238 Current share...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | ₹288m |
| Dec 31 2025 | n/a | n/a | ₹197m |
| Sep 30 2025 | n/a | n/a | ₹261m |
| Jun 30 2025 | n/a | n/a | ₹336m |
| Mar 31 2025 | ₹15m | ₹14m | ₹348m |
| Dec 31 2024 | n/a | n/a | ₹494m |
| Sep 30 2024 | n/a | n/a | ₹404m |
| Jun 30 2024 | n/a | n/a | ₹374m |
| Mar 31 2024 | ₹20m | ₹13m | ₹357m |
| Dec 31 2023 | n/a | n/a | ₹330m |
| Sep 30 2023 | n/a | n/a | ₹467m |
| Jun 30 2023 | n/a | n/a | ₹486m |
| Mar 31 2023 | ₹8m | ₹8m | ₹500m |
| Dec 31 2022 | n/a | n/a | ₹513m |
| Sep 30 2022 | n/a | n/a | ₹471m |
| Jun 30 2022 | n/a | n/a | ₹484m |
| Mar 31 2022 | ₹6m | ₹6m | ₹446m |
| Dec 31 2021 | n/a | n/a | ₹383m |
| Sep 30 2021 | n/a | n/a | ₹364m |
| Jun 30 2021 | n/a | n/a | ₹326m |
| Mar 31 2021 | ₹5m | ₹5m | ₹313m |
| Dec 31 2020 | n/a | n/a | ₹293m |
| Sep 30 2020 | n/a | n/a | ₹290m |
| Jun 30 2020 | n/a | n/a | ₹293m |
| Mar 31 2020 | ₹5m | ₹5m | ₹287m |
보상 대 시장: Harin의 총 보수(USD158.09K)는 Indian 시장에서 비슷한 규모 기업의 평균(USD256.95K)보다 낮습니다.
보상과 수익: Harin의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Harin Kanani (50 yo)
less than a year
재임 기간
₹15,000,000
보수
Dr. Harin Haridas Kanani, Ph D serves as the Managing Director of Neogen Chemicals Limited since July 22, 2017 and serves as its Executive Director since July 15, 2013. Dr. Kanani served as Joint Managing...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| MD & Executive Director | less than a year | ₹15.00m | 17.02% ₹ 9.1b | |
| Director of Operations & Whole Time Director | no data | ₹12.50m | 0.00029% ₹ 155.3k | |
| Chief Financial Officer | 1.8yrs | 데이터 없음 | 데이터 없음 | |
| Company Secretary & Compliance Officer | 6.7yrs | ₹690.56k | 데이터 없음 | |
| Senior General Manager of Marketing | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Human Resource | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Business Development | 2.8yrs | 데이터 없음 | 데이터 없음 |
2.3yrs
평균 재임 기간
50yo
평균 나이
경험이 풍부한 관리: NEOGEN의 경영진은 경험이 있음으로 간주됩니다(평균 재임 2.3 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| MD & Executive Director | 13yrs | ₹15.00m | 17.02% ₹ 9.1b | |
| Director of Operations & Whole Time Director | 11yrs | ₹12.50m | 0.00029% ₹ 155.3k | |
| Non-Executive Non-Independent Chairman | 9.2yrs | 데이터 없음 | 0.82% ₹ 440.0m | |
| Chairman Emeritus | 37.3yrs | ₹15.00m | 6.41% ₹ 3.4b | |
| Independent Non-Executive Director | 7.8yrs | ₹400.00k | 데이터 없음 | |
| Independent Non-Executive Woman Director | 7.8yrs | ₹500.00k | 데이터 없음 | |
| Independent Director | 1.9yrs | ₹200.00k | 0.0011% ₹ 589.0k | |
| Independent Director | 1.8yrs | ₹200.00k | 데이터 없음 |
8.5yrs
평균 재임 기간
67yo
평균 나이
경험이 풍부한 이사회: NEOGEN의 이사회는 경험이 있음으로 간주됩니다(평균 재임 8.5 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/07 19:54 |
| 종가 | 2026/07/07 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2026/03/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Neogen Chemicals Limited는 16명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| null null | Asian Markets Securities Private Limited |
| Vijayaraghavan Swaminathan | Avendus Spark |